Galapagos NV ADR (GLPG) Stock Analysis — PE Ratio, PS Ratio, Intrinsic Value & 2030 Price Target
Galapagos NV ADR stock (GLPG) is currently trading at $29.80. Galapagos NV ADR PS ratio (Price-to-Sales) is 1.90. Analyst consensus price target for GLPG is $27.38. WallStSmart rates GLPG as Underperform.
- GLPG PE ratio analysis and historical PE chart
- GLPG PS ratio (Price-to-Sales) history and trend
- GLPG intrinsic value — DCF, Graham Number, EPV models
- GLPG stock price prediction 2025 2026 2027 2028 2029 2030
- GLPG fair value vs current price
- GLPG insider transactions and insider buying
- Is GLPG undervalued or overvalued?
- Galapagos NV ADR financial analysis — revenue, earnings, cash flow
- GLPG Piotroski F-Score and Altman Z-Score
- GLPG analyst price target and Smart Rating
Galapagos NV ADR
📊 No data available
Try selecting a different time range
Smart Analysis
Galapagos NV ADR (GLPG) · 9 metrics scored
Smart Score
Category Performance
WallStSmart pulls financial metrics like revenue growth, profit margins, and valuation ratios and scores each one from 0 to 10 based on how strong or weak it is. Those 10 scores are grouped into 4 categories: Growth, Profitability, Valuation, and Quality — which form the 4 axes of the spider chart you see. The categories are then combined into a final score out of 100, but not equally. Growth and Profitability together count for 60% of the total, because a fast-growing profitable business matters more than just a cheap one. That final number maps to a rating (Strong Buy, Buy, Hold, Avoid) and a letter grade, giving you one clear Stock Rating.
Investment Thesis
Strong fundamentals in price/sales, price/book, eps growth. Concerns around return on equity and operating margin. Mixed signals suggest waiting for clearer direction before acting.
Galapagos NV ADR (GLPG) Key Strengths (4)
Trading below book value, meaning the market prices it less than net assets
Earnings per share surging 74.80% year-over-year
Paying $1.90 for every $1 of annual revenue
Mid-cap company balancing growth potential with stability
Supporting Valuation Data
Galapagos NV ADR (GLPG) Areas to Watch (5)
Company is destroying shareholder value
Losing money on operations
Company is losing money with a negative profit margin
Low institutional interest, mostly retail-driven
Solid revenue growth at 18.90% per year
Supporting Valuation Data
Galapagos NV ADR (GLPG) Detailed Analysis Report
Overall Assessment
This company scores 47/100 in our Smart Analysis, earning a D+ grade. Out of 9 metrics analyzed, 4 register as strengths (avg 8.8/10) while 5 fall into concern territory (avg 2.0/10). The category breakdown reveals uneven performance, with some areas requiring attention.
The Bull Case
The strongest argument centers on Price/Book, EPS Growth, Price/Sales. Valuation metrics including Price/Sales (1.90), Price/Book (0.75) suggest the stock is attractively priced. Growth metrics are encouraging with EPS Growth at 74.80%.
The Bear Case
The primary concerns are Return on Equity, Operating Margin, Profit Margin. Growth concerns include Revenue Growth at 18.90%, which may limit upside. Profitability pressure is visible in Return on Equity at -16.70%, Operating Margin at -58.60%, Profit Margin at -151.90%.
Key Dynamics to Monitor
Three factors to monitor going forward. First, whether Return on Equity improves, as this is the primary drag on the overall score. Second, margin trajectory, with Return on Equity at -16.70% needing improvement to support the investment thesis. Third, growth sustainability, with Revenue Growth at 18.90% needing to reaccelerate.
Risk Considerations
Based on the metric profile, this is a higher risk investment. There are more areas of concern than strength, warranting a more conservative position size. Investors should size positions according to their risk tolerance and maintain diversification.
Bottom Line
Fundamental challenges outweigh strengths at current levels. Return on Equity and Operating Margin are the primary drags. Consider waiting for meaningful improvement before committing capital.
Disclaimer: Smart Analysis is a scoring system developed by WallStSmart Team. Scores update daily using multi-model valuation framework. Always conduct your own research and consult with financial advisors before making investment decisions.
GLPG Price-to-Sales(PS) Ratio Chart
Historical valuation based on market cap ÷ trailing 12-month revenue
GLPG's Price-to-Sales ratio of 1.90x trades at a deep discount to its historical average of 27.61x (1th percentile). The current valuation is 98% below its historical high of 107.7x set in Sep 2016, and 1% above its historical low of 1.88x in Mar 2026. Over the past 12 months, the PS ratio has compressed from ~6.1x as trailing revenue scaled faster than the stock price.
WallStSmart Analysis Synopsis
Data-driven financial summary for Galapagos NV ADR (GLPG) · HEALTHCARE › BIOTECHNOLOGY
The Big Picture
Galapagos NV ADR is a strong growth company balancing expansion with improving profitability. Revenue reached 287M with 19% growth year-over-year. The company is currently unprofitable, posting a -151.9% profit margin.
Key Findings
Spending 37% of revenue (107M) on R&D, reinforcing its commitment to innovation and future growth.
The company is unprofitable with a -151.9% profit margin. The path to breakeven will be the key catalyst.
Free cash flow is -43M, meaning the company is burning cash. This may be acceptable for high-growth companies investing heavily.
What to Watch Next
Sector dynamics: monitor BIOTECHNOLOGY industry trends, competitive moves, and regulatory changes that could impact Galapagos NV ADR.
Bottom Line
Galapagos NV ADR offers an attractive blend of growth (19% revenue expansion) and improving fundamentals. The company is transitioning from pure growth to profitable growth, a critical inflection point. Watch for sustained margin expansion as the key signal.
This synopsis is generated from publicly available financial data. It is not financial advice. Always conduct your own research and consult a qualified financial advisor before making investment decisions.
Insider Transactions
Loading insider activity...
About Galapagos NV ADR(GLPG)
NASDAQ
HEALTHCARE
BIOTECHNOLOGY
USA
Galapagos NV, a clinical-stage biotechnology company, discovers, develops and markets several small molecule drugs. The company is headquartered in Mechelen, Belgium.